Status:
COMPLETED
Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST)
Lead Sponsor:
General Hospital of Shenyang Military Region
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The current guideline recommends to give antithrombotic treatment 24 hours after intravenous thrombolysis in acute ischemic stroke. However, early neurological deterioration will occur in some patient...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old;
- Acute ischemic stroke patients who received intravenous thrombolysis within 4.5 hours of onset;
- NIHSS ≤ 5 within 6 hours after the end of intravenous thrombolysis, and no bleeding transformation was found in head CT examination;
- Premorbid mRS ≤ 1;
- Signed informed consent.
Exclusion
- Premorbid mRS≥2;
- Uncontrolled severe hypertension (systolic pressure \>180 mmHg or diastolic pressure \>110 mmHg after drug treatment);
- Antithrombotic treatment within 24 hours before randomization;
- Significant dysphagia and inability to take the experimental drug orally;
- Allergy or contraindication to study drugs;
- Comorbidity with any serious diseases and life expectancy is less than half a year;
- Participating in other clinical trials within three months;
- Patients not suitable for this clinical study considered by researcher
Key Trial Info
Start Date :
July 8 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 25 2024
Estimated Enrollment :
1022 Patients enrolled
Trial Details
Trial ID
NCT05193071
Start Date
July 8 2022
End Date
October 25 2024
Last Update
October 31 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hui-sheng Chen
Shenyang, None Selected, China, 110840
2
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China, 110016